Robert Steven Sikorski
Keine laufenden Positionen mehr
Profil
Robert Steven Sikorski formerly worked at Amgen, Inc., as Director-Global Oncology Research & Development from 2006 to 2010, Medimmune, Inc., as Senior Director from 2010 to 2014, Five Prime Therapeutics, Inc., as Senior Vice President-Special Projects in 2017, and MedNav, Inc., as Chief Technology Officer from 1998 to 2003.
Dr. Sikorski received his graduate degree and doctorate degree from The Johns Hopkins University School of Medicine.
Ehemalige bekannte Positionen von Robert Steven Sikorski
| Unternehmen | Position | Ende |
|---|---|---|
| FIVE PRIME THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 20.03.2017 |
| Medimmune, Inc. | Corporate Officer/Principal | 01.09.2014 |
| AMGEN INC. | Corporate Officer/Principal | 01.12.2010 |
MedNav, Inc.
 MedNav, Inc. Packaged SoftwareTechnology Services MedNav, Inc. develops mobile health applications. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2003 |
Ausbildung von Robert Steven Sikorski
| The Johns Hopkins University School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| AMGEN INC. | Health Technology |
| Private Unternehmen | 3 |
|---|---|
Five Prime Therapeutics, Inc.
 Five Prime Therapeutics, Inc. BiotechnologyHealth Technology Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C. | Health Technology |
MedNav, Inc.
MedNav, Inc. Packaged SoftwareTechnology Services MedNav, Inc. develops mobile health applications. | Technology Services |
| Medimmune, Inc. | Health Technology |
